p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: Possible implications for melanoma progression

被引:87
|
作者
Sviderskaya, EV
Gray-Schopfer, VC
Hill, SP
Smit, NP
Evans-Whipp, TJ
Bond, J
Hill, L
Bataille, V
Peters, G
Kipling, D
Wynford-Thomas, D
Bennett, DC
机构
[1] St George Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England
[2] Canc Res UK, London Inst, London, England
[3] St Thomas Hosp, Twin Res & Genet Epidemiol Unit, London, England
[4] Univ Wales Coll Med, Dept Pathol, Cardiff CF4 4XN, S Glam, Wales
[5] Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands
关键词
D O I
10.1093/jnci/95.10.723
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The melanoma susceptibility locus cyclin-dependent kinase inhibitor 2A encodes two unrelated cell growth inhibitors, p16 and alternative reading frame (ARF). In fibroblasts, both proteins are implicated in cellular senescence, a key barrier to tumor development. The p16 coding sequence is more often mutated in melanoma families than is the ARF sequence. To investigate the role of p16 in melanocytes, we assessed aspects of growth, apoptosis, and immortalization in melanocytes cultured from two melanoma patients, both of whom had two inactive p16 alleles but functional ARF. Methods: Growth and senescence were evaluated by cumulative population-doubling curves, and apoptosis by terminal deoxytransferase labeling. Expression of p53 and p21, which are associated with fibroblast senescence, was assessed by immunoblotting. Amphotropic retroviruses were used to transfer exogenous gene sequences into the melanocytes. Results: Both melanocyte cultures showed high rates of apoptosis, which were reduced when the cells were grown in the presence of keratinocyte feeder cells or human stem cell factor plus endothelin 1. With these growth factors, both cultures proliferated for 45-55 net population doublings,, markedly longer than the maximum of 10 net population doublings of normal adult human melanocytes in similar media, indicating impaired senescence. One of the cultures developed chromosomal aberrations, with numerous dicentric chromosomes at senescence, consistent with telomere dysfunction. p53 and p21 levels were not elevated in senescent normal melanocytes but were elevated in senescent p16-deficient melanocytes. Interference with p53 function by transfer of human papillomavirus 16-E6 further extended the lifespan of p16-deficient melanocytes. Human telomerase reverse transcriptase was sufficient to immortalize both these cell strains but not normal melanocytes. Conclusion: Normal senescence in human melanocytes requires p16 activity. p53 contributes to a delayed form of senescence that requires telomere shortening, in p16-deficient melanocytes. These findings provide some basis for the role of p16 in melanoma susceptibility.
引用
收藏
页码:723 / 732
页数:10
相关论文
共 50 条
  • [1] Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies
    Looi, Koksun
    Megliorino, Roxanne
    Shi, Fu-Dong
    Peng, Xuan-Xian
    Chen, Yao
    Zhang, Jian-Ying
    ONCOLOGY REPORTS, 2006, 16 (05) : 1105 - 1110
  • [2] Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts
    Alcorta, DA
    Xiong, Y
    Phelps, D
    Hannon, G
    Beach, D
    Barrett, JC
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) : 13742 - 13747
  • [3] Cyclin-dependent kinase inhibitor 2A (p16) distinguishes well-differentiated liposarcoma from lipoma
    Gonzalez, Raul S.
    McClain, Colt M.
    Chamberlain, Ben K.
    Coffin, Cheryl M.
    Cates, Justin M. M.
    HISTOPATHOLOGY, 2013, 62 (07) : 1109 - 1111
  • [4] Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A/P16) Polymorphisms and Risk of Pancreatic Neuroendocrine Tumors
    Campa, D.
    Rizzato, C.
    Capurso, G.
    Delle Fave, G.
    Gazouli, M.
    Landi, S.
    Buechler, M. W.
    Malecka-Panas, E.
    Boggi, U.
    Andriulli, A.
    Scarpa, A.
    Pasquali, C.
    Canzian, F.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 85 - 85
  • [5] Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease
    Arendt, T
    Rodel, L
    Gartner, U
    Holzer, M
    NEUROREPORT, 1996, 7 (18) : 3047 - 3049
  • [6] HOMOZYGOUS LOSS OF THE CYCLIN-DEPENDENT KINASE 4-INHIBITOR (P16) GENE IN HUMAN LEUKEMIAS
    OGAWA, S
    HIRANO, N
    SATO, N
    TAKAHASHI, T
    HANGAISHI, A
    TANAKA, K
    KUROKAWA, M
    TANAKA, T
    MITANI, K
    YAZAKI, Y
    HIRAI, H
    BLOOD, 1994, 84 (08) : 2431 - 2435
  • [7] Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer
    Lee, CT
    Capodieci, P
    Osman, I
    Fazzari, M
    Ferrara, J
    Scher, HI
    Cordon-Cardo, C
    CLINICAL CANCER RESEARCH, 1999, 5 (05) : 977 - 983
  • [8] ABSENCE OF GERMLINE MUTATIONS INVOLVING THE CYCLIN-DEPENDENT KINASE-4 INHIBITOR (P16) GENE IN UVEAL MELANOMA
    SINGH, AD
    NAGAI, H
    CROCE, CM
    DONOSO, LA
    SHIELDS, JA
    SHIELDS, CL
    HUEBNER, K
    OHTA, M
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1995, 36 (04) : S770 - S770
  • [9] Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts
    Stein, GH
    Drullinger, LF
    Soulard, A
    Dulic, V
    MOLECULAR AND CELLULAR BIOLOGY, 1999, 19 (03) : 2109 - 2117
  • [10] EXPRESSION OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P16 DURING THE ONGOING CELL-CYCLE
    SOUCEK, T
    PUSCH, O
    HENGSTSCHLAGEROTTNAD, E
    WAWRA, E
    BERNASCHEK, G
    HENGSTSCHLAGER, M
    FEBS LETTERS, 1995, 373 (02) : 164 - 169